VIVA Biotech Holdings
HKEX:1873
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (8.4), the stock would be worth HK$1.31 (24% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11 | HK$1.72 |
0%
|
| 3-Year Average | 8.4 | HK$1.31 |
-24%
|
| 5-Year Average | 13.1 | HK$2.04 |
+19%
|
| Industry Average | 26.8 | HK$4.18 |
+143%
|
| Country Average | 28.9 | HK$4.52 |
+163%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
V
|
VIVA Biotech Holdings
HKEX:1873
|
3.6B HKD | 11 | 14.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.6B USD | 25.8 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 25.9 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.1 | 15.5 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 25.4 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 22 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 38.4 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 17.2 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 24.7 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
VIVA Biotech Holdings
Glance View
Viva Biotech Holdings engages in preclinical research and development of innovative drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The firm operates its businesses mainly in the United States, China, Europe and other regions.
